Compare TONX & CLLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TONX | CLLS |
|---|---|---|
| Founded | N/A | 1999 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 147.6M | 139.0M |
| IPO Year | 2013 | 2014 |
| Metric | TONX | CLLS |
|---|---|---|
| Price | $3.22 | $1.13 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $4.83 |
| AVG Volume (30 Days) | ★ 258.1K | 87.1K |
| Earning Date | 11-10-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 69.21 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $32,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $10.70 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 433.33 | N/A |
| 52 Week Low | $1.75 | $0.88 |
| 52 Week High | $4.44 | $5.45 |
| Indicator | TONX | CLLS |
|---|---|---|
| Relative Strength Index (RSI) | 50.91 | 47.78 |
| Support Level | $3.15 | $0.94 |
| Resistance Level | $3.60 | $1.28 |
| Average True Range (ATR) | 0.33 | 0.12 |
| MACD | 0.07 | 0.06 |
| Stochastic Oscillator | 45.51 | 40.01 |
TON Strategy Co is a digital asset treasury and Web3 ecosystem company focused on supporting The Open Network, a public blockchain integrated with Telegram and designed for fast, scalable transactions and decentralized applications. Its core business is managing its holdings of Toncoin (TON), including staking tokens to support network validation and earn rewards, while adhering to regulatory, accounting, and risk management standards. The company also pursues Web3 initiatives to support the ecosystem's growth and adoption. It operates through MARKET. live, Go Fund Yourself, and TON segments, with MARKET.live generating maximum revenue as a multi-vendor livestream shopping platform that combines e-commerce and entertainment across social and video channels.
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.